Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RORC | P51449 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17434515 | 0.82 | ALDH1A1 (0.54) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL18677472 | 0.80 | ALDH1A1 (0.57) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL12354889 | 0.79 | ALDH1A1 (0.56) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL16722682 | 0.78 | IDO1 (0.60) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL13401640 | 0.77 | KMT2A (0.56) | ALDH1A1LMNAGAAKMT2ARORC | |
| SCHEMBL17434565 | 0.77 | ALDH1A1 (0.52) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL15899329 | 0.77 | RORC (0.66) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL20941563 | 0.77 | ALDH1A1 (0.54) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL307278 | 0.77 | IDO1 (0.62) | IDO1ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL1798542 | 0.76 | KDM4E (0.51) | ALDH1A1LMNAGAAHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | IDO1 316/4885ALDH1A1 312/4885LMNA 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.